Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on EquityReturn on Sales

Summit Therapeutics (SMMT) EBIT Margin (2016 - 2024)

Historic EBIT Margin for Summit Therapeutics (SMMT) over the last 6 years, with Q3 2022 value amounting to 7700.0%.

  • Summit Therapeutics' EBIT Margin changed N/A to 7700.0% in Q3 2022 from the same period last year, while for Dec 2024 it was 2903.65%, marking a year-over-year increase of 5.565152039566833e22%. This contributed to the annual value of 10225.39% for FY2022, which is 54611000.0% down from last year.
  • Summit Therapeutics' EBIT Margin amounted to 7700.0% in Q3 2022.
  • In the past 5 years, Summit Therapeutics' EBIT Margin ranged from a high of 64.53% in Q3 2018 and a low of 7700.0% during Q3 2022
  • Its 4-year average for EBIT Margin is 2575.37%, with a median of 1507.33% in 2019.
  • Its EBIT Margin has fluctuated over the past 5 years, first skyrocketed by 1621200bps in 2018, then crashed by -49526300bps in 2019.
  • Quarter analysis of 4 years shows Summit Therapeutics' EBIT Margin stood at 1385.05% in 2018, then plummeted by -348bps to 6205.65% in 2019, then skyrocketed by 62bps to 2343.08% in 2020, then tumbled by -229bps to 7700.0% in 2022.
  • Its last three reported values are 7700.0% in Q3 2022, 2343.08% for Q1 2020, and 6205.65% during Q4 2019.